Allurion Technologies (ALUR) said Thursday that initial trial results from the Allurion balloon in combination with semaglutide showed total body weight loss and lean body mass gains.
The company treated 52 patients in the study and the average total body weight loss was 20.3% after eight months while the lean body mass increased by 15%, according to the company.
Shares of the company were up 29% in recent after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。